InSilicoTrials and Galileo Research have partnered to apply in silico services to drug repositioning activities and provide mutual support in modeling and simulation activities.
The partnership will combine the know-how and services of both companies to leverage Galileo Research’s experience and knowledge and the skills needed to bring pharmaceuticals, medical devices, dietary supplements and cosmetics to market. I will utilize it. InSilicoTrials’ extensive expertise in computational modeling and simulation, IT and cloud solutions for the life sciences sector.
The first step in the collaboration is to use the InSilicoTrials solution available on a cloud-based platform to relocate existing molecules into new therapeutic areas and indications (drug repositioning). Galileo Research uses the collected results to develop proof-of-concept studies and in vitro tests in accordance with regulatory and scientific requirements.
Luca Emili, CEO and Founder of InSilicoTrials, commented: The purpose of this partnership with Galileo Research is to leverage modeling and simulation to innovate R & D. Our simulation platform can process vast numbers of compounds in minutes instead of months, while increasing knowledge about drug safety and significantly reducing costs, according to regulatory guidelines. “
Alberto Bresci, CEO of Galileo Research, said: This collaboration offers a great opportunity for both partners. The in silico approach is expected to grow over the next few years and will be strongly recommended from a regulatory standpoint, but it still requires experimental supporting data. We believe this partnership will help R & D maximize results by reducing costs, time, and turnover. “
Silvia Trasciatti, CSO of Galileo Research, said: Galileo Research has always endeavored to minimize animal testing. Thanks to the in silico method provided by InSilicoTrials, we will continue to focus on developing alternative procedures and develop new strategies for assessing drug safety and efficacy, not only through traditional laboratory animal studies, but preferably through target-specific mechanisms. Can be implemented. Based on in vitro biological research, R & D is also speeding up. “
InSilicoTrials and Galileo Research are partnering to reduce time and cost of drug development
Source link InSilicoTrials and Galileo Research are partnering to reduce time and cost of drug development